 |
strona: 124 z 161 |
|
|
|
 |
2011.01.02 |
Honda Achieves First Flight of FAA-Conforming HondaJet
Greensboro, North Carolina, USA - December 21, 2010 - Honda Aircraft Company, Inc., today announced that it has successfully completed the first flight of its FAA-conforming HondaJet advanced light business jet. The event is a significant step in Honda's aerospace program leading to delivery of aircraft in 2012.
|
 |
|
2011.01.02 |
Atos Origin and Siemens to create a European IT Champion
Munich, Germany / Paris, France - December 14, 2010 - Atos Origin and Siemens announce their intention to form a global strategic partnership. Siemens will contribute its Siemens IT Solutions and Services for a total sum of EUR850 million to Atos Origin in order to create a European IT champion.
|
| |
|
2010.12.26 |
NATO and IBM to Use Cloud Technology for Improved Command and Control
Norfolk, Virginia and Washington, D.C., USA - December 22, 2010 - NATO's Allied Command Transformation (ACT) today selected IBM (NYSE: IBM) for a strategic technology project to gain experience with emerging information technologies to improve data center efficiency and increase data sharing by its 28 member nations.
|
| |
|
2010.12.25 |
Inteligentna sieć energetyczna Mitsubishi Corp.
Tokyo, Japonia - 21 grudnia 2010 - Firmy Mitsubishi Corporation (MC), Mitsubishi Motors Corporation (MMC) oraz Mitsubishi Electric Corporation (MELCO) zdecydowały się na partnerską współpracę w ramach projektu badawczego prowadzonego przez japońską rządową Agencję Nowych Źródeł Energii i Rozwoju Technologii Przemysłowych (NEDO).
|
| |
|
2010.12.25 |
Accuray Establishes Medical Affairs Function to accelerate CyberKnife
Sunnyvale, Calif., USA - December 17, 2010 - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company has established a Medical Affairs function to accelerate CyberKnife data collection, utilization and referral patterns and to provide strategic guidance on clinically driven processes, innovations and initiatives.
|
| |
|
2010.12.19 |
U.S. ETF and ETP Assets Break Through $1 Trillion Milestone
New York, USA - December 17, 2010 - Assets in U.S.-listed exchange traded funds (ETFs) and exchange traded products (ETPs) broke through the $1 trillion milestone - reaching $1.027 trillion - for the first time on 16 December 2010, according to BlackRock's Global ETF Research and Implementation Strategy Team.
|
| |
|
2010.12.18 |
GlaxoSmithKline partnerem "Koalicji na rzecz odpowiedzialnego biznesu"
Warszawa, 15 grudnia 2010 - Podczas konferencji zatytułowanej "Przedsiębiorca, pracownik, urzędnik, konsument. Kogo dotyczy odpowiedzialny biznes?" zainaugurowano działalność "Koalicji na rzecz odpowiedzialnego biznesu". Partnerem Koalicji reprezentującym branżę farmaceutyczną jest GlaxoSmithKline.
|
| |
|
2010.12.12 |
Cloud computing: the latest chapter in an epic journey
Mountain View, Calif., USA - December 10, 2010 - In the first half of next year Chrome notebooks will be available for sale from Acer and Samsung. Travelers flying on AirTran, Delta or Virgin America between November 20, 2010 and January 2, 2011 have free Wi-Fi on any of their domestic flights to check email, watch videos and surf the web from 30,000 feet above the ground.
|
| |
|
2010.12.11 |
33rd Annual CTRC-AACR Breast Cancer Symposium
The 2010 CTRC-AACR San Antonio Breast Cancer Symposium - held December 8-12, 2010 - is presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine.
|
| |
|
2010.12.11 |
GlaxoSmithKline: Data from Tykerb investigational phase III studies
London, UK and Philadelphia, USA - December 10, 2010 - Topline results were presented today from two Phase III studies examining the effect of Tykerb (lapatinib) in the neo-adjuvant setting of HER2-positive breast cancer. The combination of lapatinib and trastuzumab, with standard chemotherapy, was compared to standard chemotherapy plus either lapatinib or trastuzumab in a trial called NeoALTTO.
|
| |
|
2010.12.11 |
Combination Therapy Reduced HER2-positive Breast Cancers
San Antonio, USA - December 10, 2010 - A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.
|
| |
|
|
strona: 124 z 161 |
|
|
|
|
|
|
subskrypcja RSS
poprzednia
